LEADER 04335nam 2201141z- 450 001 9910346664803321 005 20231214133547.0 010 $a3-03897-917-1 035 $a(CKB)4920000000095019 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/45509 035 $a(EXLCZ)994920000000095019 100 $a20202102d2019 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aDrug metabolism, pharmacokinetics and bioanalysis /$fspecial issue editors, Hye Suk Lee, Kwang-Hyeon Liu 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 215 $a1 electronic resource (230 p.) 311 $a3-03897-916-3 330 $aDrug metabolism/pharmacokinetics and drug interaction studies have been extensively carried out in order to secure the druggability and safety of new chemical entities throughout the development of new drugs. Recently, drug metabolism and transport by phase II drug metabolizing enzymes and drug transporters, respectively, as well as phase I drug metabolizing enzymes, have been studied. A combination of biochemical advances in the function and regulation of drug metabolizing enzymes and automated analytical technologies are revolutionizing drug metabolism research. There are also potential drug?drug interactions with co-administered drugs due to inhibition and/or induction of drug metabolic enzymes and drug transporters. In addition, drug interaction studies have been actively performed to develop substrate cocktails that do not interfere with each other and a simultaneous analytical method of substrate drugs and their metabolites using a tandem mass spectrometer. This Special Issue has the aim of highlighting current progress in drug metabolism/pharmacokinetics, drug interactions, and bioanalysis. 606 $aDrugs$xMetabolism 610 $ahuman liver microsomes 610 $aalcohol addiction 610 $aUGT 610 $aultra-high-pressure liquid chromatography 610 $aadalimumab 610 $aprocainamide 610 $aLC-MS/MS 610 $aDA-9805 610 $apaeonol 610 $aLC-QTOF-MS/MS 610 $aYRA-1909 610 $achlorogenic acid 610 $aimmunoprecipitation 610 $aEurycoma longifolia 610 $aCYP 610 $acaffeic acid 610 $arat 610 $apharmaceutical excipient 610 $aKorean red ginseng extract 610 $aStauntonia hexaphylla leaf extract 610 $abioanalysis 610 $aHPLC-MS/MS 610 $aB6 610 $aeurycomanone 610 $abioavailability 610 $adrying technology 610 $aGB3 610 $adiclofenac 610 $a129-Glatm1Kul/J 610 $aaglycone 610 $acaffeic acid O-glucuronides 610 $aorganic anion transporting polypeptide 610 $aprotein precipitation 610 $ametabolic stability 610 $aFabry disease 610 $abiopharmaceuticals 610 $aimperatorin 610 $aneochlorogenic acid 610 $agastric ulcer 610 $asaikosaponin a 610 $ahair 610 $aanthraquinone 610 $aacetyl tributyl citrate 610 $apharmacokinetics 610 $abrain distribution 610 $amematine 610 $aethyl glucuronide 610 $apharmacokinetic 610 $aloxoprofen 610 $aliquid chromatography-quadrupole TOF MS 610 $aglucuronidation 610 $aesomeprazole 610 $ametformin 610 $acytochrome P450 610 $aglycoside 610 $aAUDIT score 610 $aprotein stability 610 $aefficacy 610 $aLC-HR/MS 610 $acryptochlorogenic acid 610 $aaceclofenac 610 $adrug interaction 610 $aliquid chromatography-tandem mass spectrometry 610 $aOsthenol 610 $aplasma 610 $aN-acetylprocainamide 610 $adiabetes 615 0$aDrugs$xMetabolism. 676 $a615.1 702 $aLee$b Hye Suk$c(Pharmacist), 702 $aLiu$b Kwang-Hyeon 906 $aBOOK 912 $a9910346664803321 996 $aDrug Metabolism, Pharmacokinetics and Bioanalysis$93020262 997 $aUNINA